AU716151B2 - Apo B-secretion/MTP inhibitory amides - Google Patents

Apo B-secretion/MTP inhibitory amides Download PDF

Info

Publication number: AU716151B2
Authority: AU; Australia
Prior art keywords: compound; amide; trifluoromethylbiphenyl; carboxylic acid; inhibitor
Prior art date: 1996-11-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU46347/97A

Other languages

English (en)

Other versions

AU4634797A (en

Inventor

George Chang

George Joseph Quallich

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Inc

Original Assignee

Pfizer Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-27

Filing date

1997-11-03

Publication date

2000-02-17

1997-11-03 Application filed by Pfizer Inc filed Critical Pfizer Inc

1998-06-22 Publication of AU4634797A publication Critical patent/AU4634797A/en

2000-02-17 Application granted granted Critical

2000-02-17 Publication of AU716151B2 publication Critical patent/AU716151B2/en

2017-11-03 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU46347/97A 1996-11-27 1997-11-03 Apo B-secretion/MTP inhibitory amides Ceased AU716151B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3230796P	1996-11-27	1996-11-27
US60/032307		1996-11-27
PCT/IB1997/001368 WO1998023593A1 (en)	1996-11-27	1997-11-03	Apo b-secretion/mtp inhibitory amides

Publications (2)

Publication Number	Publication Date
AU4634797A AU4634797A (en)	1998-06-22
AU716151B2 true AU716151B2 (en)	2000-02-17

Family

ID=21864233

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU46347/97A Ceased AU716151B2 (en)	1996-11-27	1997-11-03	Apo B-secretion/MTP inhibitory amides

Country Status (34)

Country	Link
US (1)	US6121283A (is)
EP (1)	EP0944602A1 (is)
JP (1)	JP3270764B2 (is)
KR (1)	KR100334567B1 (is)
CN (2)	CN1238764A (is)
AP (1)	AP804A (is)
AR (1)	AR010309A1 (is)
AU (1)	AU716151B2 (is)
BG (2)	BG108830A (is)
BR (1)	BR9714364A (is)
CA (1)	CA2272719C (is)
CZ (1)	CZ292160B6 (is)
DZ (1)	DZ2358A1 (is)
EA (1)	EA001539B1 (is)
GT (1)	GT199700122A (is)
HN (1)	HN1997000144A (is)
HR (1)	HRP970642A2 (is)
ID (1)	ID18995A (is)
IL (1)	IL129744A0 (is)
IS (1)	IS5040A (is)
MA (1)	MA26451A1 (is)
NO (1)	NO312760B1 (is)
NZ (1)	NZ335162A (is)
OA (1)	OA11050A (is)
PA (1)	PA8441601A1 (is)
PE (1)	PE17199A1 (is)
SK (1)	SK65499A3 (is)
TN (1)	TNSN97193A1 (is)
TR (1)	TR199901180T2 (is)
TW (1)	TW502023B (is)
UY (1)	UY24789A1 (is)
WO (1)	WO1998023593A1 (is)
YU (1)	YU23499A (is)
ZA (1)	ZA9710641B (is)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6262277B1 (en)	1994-09-13	2001-07-17	G.D. Searle And Company	Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5919795A (en) *	1995-06-07	1999-07-06	Pfizer Inc.	Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion
GB9708805D0 (en)	1997-05-01	1997-06-25	Smithkline Beecham Plc	Compounds
US5968950A (en) *	1997-06-23	1999-10-19	Pfizer Inc	Apo B-secretion/MTP inhibitor hydrochloride salt
GB9810876D0 (en)	1998-05-20	1998-07-22	Smithkline Beecham Plc	Compounds
AU4543899A (en)	1998-06-08	1999-12-30	Advanced Medicine, Inc.	Multibinding inhibitors of microsomal triglyceride transferase protein
PE20001088A1 (es)	1998-10-08	2000-12-02	Smithkline Beecham Plc	Compuestos derivados de tetrahidrobenzazepina
GB9826412D0 (en)	1998-12-03	1999-01-27	Glaxo Group Ltd	Chemical compounds
DE69908414T2 (de) *	1998-12-23	2004-04-01	G.D. Searle Llc, Chicago	Kombinationen von ileumgallensäuretransports inhibitoren und cholesteryl ester transfer protein inhibitoren
CZ20012344A3 (cs) *	1998-12-23	2002-01-16	G. D. Searle Llc	Kombinace pro kardiovaskulární indikace
DE19929012A1 (de) *	1999-06-25	2000-12-28	Bayer Ag	Kombination von MTP-Inhibitoren und stoffwechselbeeinflussenden Wirkstoffen und ihre Verwendung in Arzneimitteln
DE19929065A1 (de) *	1999-06-25	2000-12-28	Bayer Ag	Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
DE19929031A1 (de) *	1999-06-25	2000-12-28	Bayer Ag	Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln
AU6824700A (en) *	1999-07-20	2001-02-05	Novartis Ag	Organic compounds
IL139449A0 (en) *	1999-11-10	2001-11-25	Pfizer Prod Inc	Use of apo b secretion/mtp inhibitors
CA2324800A1 (en) *	1999-11-10	2001-05-10	Mary Anne Hickman	Use of apo b secretion/mtp inhibitors
IL139450A0 (en) *	1999-11-10	2001-11-25	Pfizer Prod Inc	Methods of administering apo b-secretion/mtp inhibitors
CA2324801A1 (en) *	1999-11-10	2001-05-10	Andrew Gordon Swick	Use of apo b secretion/mtp inhibitors and anti-obesity agents
JP3897594B2 (ja)	2000-01-18	2007-03-28	ノバルティスアクチエンゲゼルシャフト	ミクロソームトリグリセリド輸送タンパク質およびアポリポタンパク質分泌の阻害剤として有用なカルボキサミド
AU6011301A (en) *	2000-03-14	2001-09-24	Actelion Pharmaceuticals Ltd	1,2,3,4-tetrahydroisoquinoline derivatives
AU2001262185A1 (en) *	2000-04-10	2001-10-23	Novartis Ag	Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
GB0013383D0 (en) *	2000-06-01	2000-07-26	Glaxo Group Ltd	Therapeutic benzamide derivatives
GB0013346D0 (en) *	2000-06-01	2000-07-26	Glaxo Group Ltd	Therapeutic benzamide derivatives
WO2002014276A1 (fr) *	2000-08-10	2002-02-21	Tanabe Seiyaku Co., Ltd.	Composes a base de benzoylaminoisoindoline, leurs procedes de preparation et produits intermediaires utilises dans leur synthese
AU2001277728A1 (en) *	2000-08-10	2002-02-25	Tanabe Seiyaku Co., Ltd.	Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
RU2246302C2 (ru) *	2000-09-01	2005-02-20	Санкио Компани, Лимитед	Фармацевтическая композиция для профилактики и лечения нарушений липидного обмена
JO2654B1 (en)	2000-09-04	2012-06-17	شركة جانسين فارماسوتيكا ان. في	Multiple aryl caroxa amides are useful as lipid - lowering agents
PL362546A1 (en) *	2000-10-05	2004-11-02	Fujisawa Pharmaceutical Co, Ltd.	Benzamide compounds as apo b secretion inhibitors
JO2409B1 (en)	2000-11-21	2007-06-17	شركة جانسين فارماسوتيكا ان. في	Second-phenyl carboxy amides are useful as lipid-lowering agents
JP2004532856A (ja) *	2001-04-30	2004-10-28	藤沢薬品工業株式会社	アポリポタンパク質ｂ阻害剤としてのビアリールカルボキサミド化合物
ATE444060T1 (de) *	2001-06-22	2009-10-15	Pfizer Prod Inc	Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
CN1522246B (zh)	2001-06-28	2010-04-21	辉瑞产品公司	三酰胺取代的吲哚、苯并呋喃及苯并噻吩
US20030144350A1 (en) *	2001-07-20	2003-07-31	Adipogenix, Inc.	Fat accumulation-modulation compounds
US20030130343A1 (en) *	2001-08-10	2003-07-10	Adipogenix, Inc.	Fat accumulation-modulating compounds
JP2005510564A (ja) *	2001-11-28	2005-04-21	藤沢薬品工業株式会社	アポリポタンパク質ｂ阻害剤としての複素環式アミド化合物
JP4865989B2 (ja) *	2002-02-01	2012-02-01	ベンド・リサーチ・インコーポレーテッド	改良された噴霧乾燥装置を使用する均質な噴霧乾燥された固体の非晶質薬物分散物を製造する方法
BR0306292A (pt) *	2002-02-28	2004-08-24	Japan Tobacco Inc	Composto de éster e uso medicinal do mesmo
JP4542341B2 (ja) *	2002-03-13	2010-09-15	ザユニバーシティオブテネシーリサーチファウンデイション	置換テトラヒドロイソキノリン化合物、調製方法、およびその使用
WO2004039795A2 (en) *	2002-10-29	2004-05-13	Fujisawa Pharmaceutical Co., Ltd.	Amide compounds for the treatment of hyperlipidemia
BR0317426A (pt) *	2002-12-20	2005-11-16	Pfizer Prod Inc	Inibidores de proteìna de transferência de triglicéridos microssomais
EP1578725A1 (en) *	2002-12-20	2005-09-28	Pfizer Products Inc.	Microsomal triglyceride transfer protein inhibitors
JP2006520810A (ja)	2003-03-17	2006-09-14	日本たばこ産業株式会社	Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法
EP1669345A4 (en) *	2003-08-29	2008-02-20	Japan Tobacco Inc	ESTER DERIVATIVE AND MEDICAL USE THEREOF
BRPI0508263B8 (pt)	2004-03-01	2021-05-25	Idorsia Pharmaceuticals Ltd	derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
CA2558766A1 (en)	2004-03-05	2005-09-22	The Trustees Of The University Of Pennsylvania	The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030623A1 (en) *	2004-07-16	2006-02-09	Noboru Furukawa	Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
US8101774B2 (en) *	2004-10-18	2012-01-24	Japan Tobacco Inc.	Ester derivatives and medicinal use thereof
KR20070072888A (ko) *	2004-10-25	2007-07-06	니뽄 다바코 산교 가부시키가이샤	용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
CA2588087A1 (en) *	2004-11-15	2006-05-18	Obe Therapy Biotechnology S.A.S.	Methods of reducing body fat
JP2006249022A (ja)	2005-03-11	2006-09-21	Sumitomo Chemical Co Ltd	４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法
JP5356017B2 (ja)	2005-04-19	2013-12-04	サーフィスロジックス，インコーポレイティッド	ミクロソームトリグリセリド転送タンパク質及びａｐｏ−ｂ分泌物の阻害剤
JP2008542255A (ja) *	2005-05-27	2008-11-27	ファイザー・プロダクツ・インク	肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
US8383660B2 (en)	2006-03-10	2013-02-26	Pfizer Inc.	Dibenzyl amine compounds and derivatives
US7919506B2 (en)	2006-03-10	2011-04-05	Pfizer Inc.	Dibenzyl amine compounds and derivatives
JP2009531314A (ja) *	2006-03-10	2009-09-03	ニューロジェン・コーポレーション	ピペラジニルオキソアルキルテトラヒドロイソキノリン類および関連類似物
EA201100812A1 (ru) *	2006-04-03	2012-06-29	Сантарис Фарма А/С	Фармацевтическая композиция
EP2194129A3 (en)	2006-04-03	2012-12-26	Santaris Pharma A/S	Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
WO2007143164A1 (en) *	2006-06-02	2007-12-13	San Diego State University Research Foundation	Compositions and methods for ameliorating hyperlipidemia
US20090042835A1 (en) *	2006-06-02	2009-02-12	Davis Roger A	Compositions and methods for ameliorating hyperlipidemia
JP2010505432A (ja) *	2006-10-09	2010-02-25	サンタリスファーマアー／エス	Ｐｃｓｋ９を調節するためのｒｎａアンタゴニスト化合物
CL2007002958A1 (es) *	2006-10-12	2008-05-09	Epix Delaware Inc	Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
ES2346014T3 (es) *	2006-10-24	2010-10-07	Janssen Pharmaceutica Nv	Derivados del acido tetrahidro-naftaleno-1-carboxilico inhibidores de mtp.
JO2653B1 (en)	2006-10-24	2012-06-17	شركة جانسين فارماسوتيكا ان. في	Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB
ES2382009T3 (es)	2006-12-01	2012-06-04	Bristol-Myers Squibb Company	Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
WO2008075949A1 (en) *	2006-12-20	2008-06-26	Friesland Brands B.V.	Modulation of human microsomal triglyceride transfer protein (mtp or mttp) gene expression by food-grade/ingested dietary microorganisms
EP2120927A1 (en) *	2006-12-21	2009-11-25	Aegerion Pharmaceuticals, Inc.	Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
EP2126079A1 (en) *	2007-03-22	2009-12-02	Santaris Pharma A/S	Rna antagonist compounds for the inhibition of apo-b100 expression
WO2008113832A2 (en) *	2007-03-22	2008-09-25	Santaris Pharma A/S	SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
JP2010531364A (ja) *	2007-06-25	2010-09-24	ニューロジェン・コーポレーション	ピペラジニルオキソアルキルテトラヒドロ−β−カルボリンおよび関連類似体
US20110054011A1 (en) *	2007-08-30	2011-03-03	Mccullagh Keith	RNA Antagonist Compounds for the Modulation of FABP4/AP2
ES2406686T3 (es) *	2007-10-04	2013-06-07	Santaris Pharma A/S	Micromirs
CA2707549A1 (en)	2007-12-03	2009-06-11	Itzik Harosh	Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
CN101925383A (zh)	2007-12-11	2010-12-22	赛特帕斯凡德株式会社	甲酰胺化合物及其作为趋化因子受体激动剂的应用
US20090197947A1 (en) *	2008-02-01	2009-08-06	The Research Foundation Of State University Of New York	Medicaments and methods for lowering plasma lipid levels and screening drugs
AU2009221064B2 (en) *	2008-03-07	2014-12-11	Roche Innovation Center Copenhagen A/S	Pharmaceutical compositions for treatment of microRNA related diseases
WO2010012667A1 (en)	2008-08-01	2010-02-04	Santaris Pharma A/S	Micro-rna mediated modulation of colony stimulating factors
WO2010122538A1 (en) *	2009-04-24	2010-10-28	Santaris Pharma A/S	Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
US8563528B2 (en)	2009-07-21	2013-10-22	Santaris Pharma A/S	Antisense oligomers targeting PCSK9
BR112015026513A2 (pt)	2013-04-17	2017-07-25	Pfizer	derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
MY183049A (en)	2013-06-27	2021-02-09	Roche Innovation Ct Copenhagen As	Antisense oligomers and conjugates targeting pcsk9
WO2015065595A1 (en)	2013-10-30	2015-05-07	Trustees Of Dartmouth College	Method for selectively inhibiting acat1 in the treatment of obesity, metabolic syndrome, and atherosclerosis
WO2016055901A1 (en)	2014-10-08	2016-04-14	Pfizer Inc.	Substituted amide compounds
CA2965336A1 (en) *	2014-10-22	2016-04-28	The Board Of Regents Of The University Of Texas System	Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof
MX2021008533A (es)	2019-01-18	2021-08-19	Astrazeneca Ab	Inhibidores de la pcsk9 y metodos de uso de los mismos.
CN113292493A (zh) *	2021-06-23	2021-08-24	上海立科化学科技有限公司	5,7-二氯-1,2,3,4-四氢异喹啉的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4022900A (en) *	1970-09-09	1977-05-10	Marion Laboratories, Inc.	Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
US5595872A (en) *	1992-03-06	1997-01-21	Bristol-Myers Squibb Company	Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) *	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
EP0832069B1 (en) *	1995-06-07	2003-03-05	Pfizer Inc.	BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION

1997
- 1997-11-03 IL IL12974497A patent/IL129744A0/xx unknown
- 1997-11-03 SK SK654-99A patent/SK65499A3/sk unknown
- 1997-11-03 TR TR1999/01180T patent/TR199901180T2/xx unknown
- 1997-11-03 EP EP97945048A patent/EP0944602A1/en not_active Withdrawn
- 1997-11-03 CA CA002272719A patent/CA2272719C/en not_active Expired - Fee Related
- 1997-11-03 US US09/284,466 patent/US6121283A/en not_active Expired - Fee Related
- 1997-11-03 EA EA199900416A patent/EA001539B1/ru not_active IP Right Cessation
- 1997-11-03 JP JP52446498A patent/JP3270764B2/ja not_active Expired - Fee Related
- 1997-11-03 BR BR9714364A patent/BR9714364A/pt not_active Application Discontinuation
- 1997-11-03 YU YU23499A patent/YU23499A/sh unknown
- 1997-11-03 WO PCT/IB1997/001368 patent/WO1998023593A1/en not_active Application Discontinuation
- 1997-11-03 CN CN97180033A patent/CN1238764A/zh active Pending
- 1997-11-03 AU AU46347/97A patent/AU716151B2/en not_active Ceased
- 1997-11-03 KR KR1019997004662A patent/KR100334567B1/ko not_active IP Right Cessation
- 1997-11-03 NZ NZ335162A patent/NZ335162A/xx unknown
- 1997-11-04 HN HN1997000144A patent/HN1997000144A/es unknown
- 1997-11-05 TW TW086116476A patent/TW502023B/zh not_active IP Right Cessation
- 1997-11-14 PA PA84416A patent/PA8441601A1/es unknown
- 1997-11-20 AP APAP/P/1997/001145A patent/AP804A/en active
- 1997-11-24 PE PE1997001062A patent/PE17199A1/es not_active Application Discontinuation
- 1997-11-25 ID IDP973763A patent/ID18995A/id unknown
- 1997-11-25 UY UY24789A patent/UY24789A1/es not_active Application Discontinuation
- 1997-11-25 GT GT199700122A patent/GT199700122A/es unknown
- 1997-11-26 ZA ZA9710641A patent/ZA9710641B/xx unknown
- 1997-11-26 MA MA24877A patent/MA26451A1/fr unknown
- 1997-11-26 TN TNTNSN97193A patent/TNSN97193A1/fr unknown
- 1997-11-26 DZ DZ970208A patent/DZ2358A1/xx active
- 1997-11-26 AR ARP970105560A patent/AR010309A1/es unknown
- 1997-11-26 HR HR60/032,307A patent/HRP970642A2/hr not_active Application Discontinuation
1999
- 1999-04-30 IS IS5040A patent/IS5040A/is unknown
- 1999-05-19 OA OA9900106A patent/OA11050A/en unknown
- 1999-05-26 NO NO19992525A patent/NO312760B1/no unknown
- 1999-05-26 BG BG108830A patent/BG108830A/bg unknown
- 1999-05-26 BG BG103434A patent/BG103434A/xx unknown
2002
- 2002-02-19 CN CN02105189A patent/CN1380289A/zh active Pending
- 2002-09-17 CZ CZ20023137A patent/CZ292160B6/cs not_active IP Right Cessation

Also Published As

Publication number	Publication date
OA11050A (en)	2002-03-07
AR010309A1 (es)	2000-06-07
NO992525L (no)	1999-05-26
HRP970642A2 (en)	1998-10-31
KR100334567B1 (ko)	2002-05-03
JP2000505810A (ja)	2000-05-16
DZ2358A1 (fr)	2002-12-28
CZ292160B6 (cs)	2003-08-13
AU4634797A (en)	1998-06-22
TNSN97193A1 (fr)	2005-03-15
IL129744A0 (en)	2000-02-29
MA26451A1 (fr)	2004-12-20
NO312760B1 (no)	2002-07-01
UY24789A1 (es)	2000-09-29
TW502023B (en)	2002-09-11
NZ335162A (en)	2000-01-28
HN1997000144A (es)	1997-12-16
ID18995A (id)	1998-05-28
WO1998023593A1 (en)	1998-06-04
US6121283A (en)	2000-09-19
CN1238764A (zh)	1999-12-15
SK65499A3 (en)	2001-05-10
PA8441601A1 (es)	2000-05-24
IS5040A (is)	1999-04-30
JP3270764B2 (ja)	2002-04-02
KR20000057269A (ko)	2000-09-15
BG108830A (bg)	2005-10-31
EA199900416A1 (ru)	1999-12-29
CA2272719C (en)	2002-10-01
CA2272719A1 (en)	1998-06-04
ZA9710641B (en)	1999-05-26
EA001539B1 (ru)	2001-04-23
PE17199A1 (es)	1999-02-19
AP9701145A0 (en)	1998-01-31
YU23499A (sh)	2001-07-10
NO992525D0 (no)	1999-05-26
BR9714364A (pt)	2000-03-21
TR199901180T2 (xx)	1999-08-23
EP0944602A1 (en)	1999-09-29
AP804A (en)	2000-01-28
CN1380289A (zh)	2002-11-20
BG103434A (en)	2000-07-31
GT199700122A (es)	1999-05-19

Publication	Publication Date	Title
AU716151B2 (en)	2000-02-17	Apo B-secretion/MTP inhibitory amides
US5919795A (en)	1999-07-06	Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion
EP0832069B1 (en)	2003-03-05	BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
EP1425010B1 (en)	2011-10-26	Substituted indoles and their use as integrin antagonists
US20040058936A1 (en)	2004-03-25	Substituted piperidines/piperazines as melanocortin receptor agonists
JP2005527492A (ja)	2005-09-15	メラノコルチン受容体アゴニスト
CA2222687A1 (en)	1996-12-05	Novel naphthyridine derivatives
EP0424929A1 (en)	1991-05-02	Isoquinolone derivatives, their production and use
EP1181954A2 (en)	2002-02-27	Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (ApoB) secretion
CZ185899A3 (cs)	2000-06-14	Amidy, farmaceutické kompozice, způsoby výroby a způsoby léčení
SK72696A3 (en)	1997-11-05	Amides and pharmauceutical compositions on their base
CA2223574C (en)	2002-04-02	Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein b (apo b) secretion
AP760A (en)	1999-09-13	Biphenyl-2-carboxylic acid-tetrahydro-isoquiolin-6-yl amide derivatives.
AU1639101A (en)	2001-04-26	Therapeutic amides and compositions containing the same
AU3585399A (en)	1999-09-16	Intermediates for the preparation of therapeutic amides
JPH11514964A (ja)	1999-12-21	ビフェニル−２−カルボン酸−テトラヒドロ−イソキノリン−６−イルアミド誘導体の製造と、ミクロソームのトリ剤グリセリド転移タンパク質および（または）アポリポ蛋白質ｂ（アポｂ）分泌の阻害としての該誘導体の使用
JPH05239030A (ja)	1993-09-17	アミノメチルテトラヒドロイソキノリン誘導体及びその製造方法

Legal Events

Date	Code	Title	Description
2000-06-15	FGA	Letters patent sealed or granted (standard patent)
2004-06-03	MK14	Patent ceased section 143(a) (annual fees not paid) or expired